DYN Quote, Financials, Valuation and Earnings

Regenxbio has a net margin of -- compared to Dyne Therapeutics's net margin of -246.3%. Dyne Therapeutics's return on equity of -- beat Regenxbio's return on equity of -69.62%.

Dyne Therapeutics has a consensus price target of --, signalling upside risk potential of 110.33%. On the other hand Regenxbio has an analysts' consensus of $37.64 which suggests that it could grow by 408.6%. Given that Regenxbio has higher upside potential than Dyne Therapeutics, analysts believe Regenxbio is more attractive than Dyne Therapeutics.

Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.243, suggesting its more volatile than the S&P 500 by 24.251%.

Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

Dyne Therapeutics quarterly revenues are --, which are smaller than Regenxbio quarterly revenues of $24.2M. Dyne Therapeutics's net income of -$97.1M is lower than Regenxbio's net income of -$59.6M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 4.19x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

Avidity Biosciences has a net margin of -- compared to Dyne Therapeutics's net margin of -3441.7%. Dyne Therapeutics's return on equity of -- beat Avidity Biosciences's return on equity of -30.66%.

Dyne Therapeutics has a consensus price target of --, signalling upside risk potential of 110.33%. On the other hand Avidity Biosciences has an analysts' consensus of $68.27 which suggests that it could grow by 117.78%. Given that Avidity Biosciences has higher upside potential than Dyne Therapeutics, analysts believe Avidity Biosciences is more attractive than Dyne Therapeutics.

Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Avidity Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avidity Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Avidity Biosciences pays out -- of its earnings as a dividend.

Dyne Therapeutics quarterly revenues are --, which are smaller than Avidity Biosciences quarterly revenues of $2.3M. Dyne Therapeutics's net income of -$97.1M is lower than Avidity Biosciences's net income of -$80.4M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Avidity Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 304.92x for Avidity Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to Dyne Therapeutics's net margin of 7.2%. Dyne Therapeutics's return on equity of -- beat Sarepta Therapeutics's return on equity of 12.48%.

Dyne Therapeutics has a consensus price target of --, signalling upside risk potential of 110.33%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.10 which suggests that it could grow by 51.85%. Given that Dyne Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Dyne Therapeutics is more attractive than Sarepta Therapeutics.

Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Dyne Therapeutics quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Dyne Therapeutics's net income of -$97.1M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 79.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 7.48x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -- compared to Dyne Therapeutics's net margin of 37.71%. Dyne Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

Dyne Therapeutics has a consensus price target of --, signalling upside risk potential of 110.33%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 20.93%. Given that Dyne Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Dyne Therapeutics is more attractive than Vertex Pharmaceuticals.

Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Dyne Therapeutics quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Dyne Therapeutics's net income of -$97.1M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 10.00x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.